High tumoral immunologic response was predominantly observed in patients with reduced cytoplasmic ENO1 expression—64% of patients with brisk tumor-infiltrating lymphocytes were characterized by low ENO1 reactivity in melanoma cells (p = 0.039). The gene discussed is ENO1; the disease is neoplasm.